Show simple item record

dc.contributor.authorDowsett, Mitch
dc.contributor.authorCuzick, Jack
dc.contributor.authorWale, Chris
dc.contributor.authorHowell, Anthony
dc.contributor.authorHoughton, Joan
dc.contributor.authorBaum, Michael
dc.date.accessioned2009-08-10T09:20:28Z
dc.date.available2009-08-10T09:20:28Z
dc.date.issued2005-10-20
dc.identifier.citationRetrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. 2005, 23 (30):7512-7 J. Clin. Oncol.en
dc.identifier.issn0732-183X
dc.identifier.pmid16234518
dc.identifier.doi10.1200/JCO.2005.01.4829
dc.identifier.urihttp://hdl.handle.net/10541/76796
dc.description.abstractPURPOSE: Arimidex, tamoxifen alone, or in combination (ATAC) trial of anastrozole (Arimidex) versus tamoxifen or a combination of the two in 9,366 postmenopausal patients with primary breast cancer found a significant improvement in disease-free survival and time to recurrence (TTR) for anastrozole compared with tamoxifen, that was restricted to patients with hormone receptor-positive (ie, estrogen receptor-positive [ER+] and/or progesterone receptor-positive [PgR+]) disease, the target population for these therapies. We retrospectively tested the hypothesis that this benefit might differ according to PgR status. PATIENTS AND METHODS: TTR was compared between the three treatment groups for subgroups defined by ER and PgR status using Cox's proportional hazards model, with and without adjustment for baseline variables. RESULTS: The unadjusted hazard ratio (HR) for anastrozole versus tamoxifen for TTR was 0.74 (95% CI, 0.64 to 0.87) for women with either ER+ or PgR+ tumors. In the ER+/PgR+ subgroup (n = 3,834) the HR was 0.84 (95% CI, 0.69 to 1.02) compared with 0.43 (95% CI, 0.31 to 0.61) in the ER+/PgR-negative (PgR-) subgroup (n = 880). In the adjusted model the HRs were 0.83 and 0.45, respectively. CONCLUSION: Time to recurrence was longer for anastrozole- than tamoxifen-treated patients in both ER+/PgR+ and ER+/PgR- subgroups, but the benefit was substantially greater in the PgR- subgroup. As this was an "exploratory" analysis, this effect should be considered as hypothesis generating and assessed prospectively in other trials comparing the adjuvant use of an aromatase inhibitor with tamoxifen.
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectCancer Recurrenceen
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshBreast Neoplasms
dc.subject.meshChemotherapy, Adjuvant
dc.subject.meshDisease-Free Survival
dc.subject.meshDouble-Blind Method
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshNeoplasm Recurrence, Local
dc.subject.meshNitriles
dc.subject.meshPostmenopause
dc.subject.meshReceptors, Estrogen
dc.subject.meshReceptors, Progesterone
dc.subject.meshRetrospective Studies
dc.subject.meshSurvival Rate
dc.subject.meshTamoxifen
dc.subject.meshTime Factors
dc.subject.meshTreatment Outcome
dc.subject.meshTriazoles
dc.titleRetrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study.en
dc.typeArticleen
dc.contributor.departmentRoyal Marsden Hospital London, SW3 6JJ United Kingdom. mitch.dowsett@icr.ac.uken
dc.identifier.journalJournal of Clinical Oncologyen
html.description.abstractPURPOSE: Arimidex, tamoxifen alone, or in combination (ATAC) trial of anastrozole (Arimidex) versus tamoxifen or a combination of the two in 9,366 postmenopausal patients with primary breast cancer found a significant improvement in disease-free survival and time to recurrence (TTR) for anastrozole compared with tamoxifen, that was restricted to patients with hormone receptor-positive (ie, estrogen receptor-positive [ER+] and/or progesterone receptor-positive [PgR+]) disease, the target population for these therapies. We retrospectively tested the hypothesis that this benefit might differ according to PgR status. PATIENTS AND METHODS: TTR was compared between the three treatment groups for subgroups defined by ER and PgR status using Cox's proportional hazards model, with and without adjustment for baseline variables. RESULTS: The unadjusted hazard ratio (HR) for anastrozole versus tamoxifen for TTR was 0.74 (95% CI, 0.64 to 0.87) for women with either ER+ or PgR+ tumors. In the ER+/PgR+ subgroup (n = 3,834) the HR was 0.84 (95% CI, 0.69 to 1.02) compared with 0.43 (95% CI, 0.31 to 0.61) in the ER+/PgR-negative (PgR-) subgroup (n = 880). In the adjusted model the HRs were 0.83 and 0.45, respectively. CONCLUSION: Time to recurrence was longer for anastrozole- than tamoxifen-treated patients in both ER+/PgR+ and ER+/PgR- subgroups, but the benefit was substantially greater in the PgR- subgroup. As this was an "exploratory" analysis, this effect should be considered as hypothesis generating and assessed prospectively in other trials comparing the adjuvant use of an aromatase inhibitor with tamoxifen.


This item appears in the following Collection(s)

Show simple item record